Siemens Healthineers Enters Agreement with HORIBA Medical
By LabMedica International staff writers Posted on 16 Oct 2017 |
Siemens Healthineers (Erlangen, Germany) and HORIBA Medical (Montpellier, France) have entered into a long-term agreement to bring new and innovative hematology solutions to the market globally.
Siemens Healthineers offers products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. HORIBA Medical designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medical laboratories, clinics and university hospitals.
With HORIBA Medical as the original equipment manufacturer to complement the Siemens Healthineers portfolio, the companies will provide customers with expanded options to fulfill their hematology and multidisciplinary solution needs. Through this alliance, Siemens Healthineers aims to help laboratories transform care delivery by providing complete multidisciplinary solutions for in vitro diagnostics testing.
"With our commercial strength and global installed base of customers combined with HORIBA Medical's innovative technologies, the relationship will expand the hematology solutions available to laboratories for diagnostics testing worldwide," said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.
“Our long-term vision and continuous investments coupled with our outstanding employees have resulted in innovative hematology technology solutions. I am extremely pleased that this long-term vision has resulted in an alliance with Siemens Healthineers” said Mr. Atsushi Horiba, Chairman, President & CEO of HORIBA, Ltd.
“This alliance provides HORIBA Medical the opportunity to address the multidisciplinary requirements along with complimentary innovative technology of Siemens Healthineers. HORIBA Medical will continue offering innovative technology solutions through its Yumizen 2 brand and current distribution channels.” said Dr. Jai Hakhu, Executive Corporate Officer of HORIBA, Ltd. and President of HORIBA Medical.
Siemens Healthineers offers products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. HORIBA Medical designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medical laboratories, clinics and university hospitals.
With HORIBA Medical as the original equipment manufacturer to complement the Siemens Healthineers portfolio, the companies will provide customers with expanded options to fulfill their hematology and multidisciplinary solution needs. Through this alliance, Siemens Healthineers aims to help laboratories transform care delivery by providing complete multidisciplinary solutions for in vitro diagnostics testing.
"With our commercial strength and global installed base of customers combined with HORIBA Medical's innovative technologies, the relationship will expand the hematology solutions available to laboratories for diagnostics testing worldwide," said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers.
“Our long-term vision and continuous investments coupled with our outstanding employees have resulted in innovative hematology technology solutions. I am extremely pleased that this long-term vision has resulted in an alliance with Siemens Healthineers” said Mr. Atsushi Horiba, Chairman, President & CEO of HORIBA, Ltd.
“This alliance provides HORIBA Medical the opportunity to address the multidisciplinary requirements along with complimentary innovative technology of Siemens Healthineers. HORIBA Medical will continue offering innovative technology solutions through its Yumizen 2 brand and current distribution channels.” said Dr. Jai Hakhu, Executive Corporate Officer of HORIBA, Ltd. and President of HORIBA Medical.
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus